Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Post by sam00122on Jul 27, 2008 4:23pm
204 Views
Post# 15333697

It all make sense

It all make senseIt all make sense. developing the proosis indication at the same time.  Well you have a big pharma that want to deal your durg or something and on the other hand you can not really figure why your future comepitor is sitting accross the table.  So develop prososis on the side while deveoping the transplant side.  The understanding that you will get money up front ie what 27 million, the name will help you overall and if they wait long enough then and they opt out, figure out were you will be with other indication.  I think mr. foster had them figured from the start.  Roche did what they did to hang the drug on a slow string but, considering the out come I think they thought they were playing softball when all the time they got invited to a hardball game.  My hat is off to you
Mr. Foster 

This is just my opinion but, I do think it might have some merit
sam 
Bullboard Posts